ArticleBJUI compass2026
Cytoreductive Radical Prostatectomy in Oligometastatic Prostate Cancer: Single-Centre Experience.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the oncological outcomes, functional recovery and overall satisfaction following cytoreductive radical prostatectomy (CRP) in patients with oligometastatic prostate cancer treated at a single tertiary-care centre. Patients and Methods: Between 2021 and 2024, 12 patients with clinically and radiologically confirmed oligometastatic prostate cancer (≤5 bone lesions, no visceral metastases) underwent open retropubic CRP after 6 months of neoadjuvant androgen deprivation therapy (ADT) and targeted radiotherapy to metastatic sites. Postoperatively, all patients received adjuvant ADT for 2 years. Perioperative details, pathological findings and functional outcomes including continence, erectile function and biochemical recurrence (BCR) were recorded prospectively and analysed with descriptive statistics. Results: The mean age was 60 years (range 55-68), mean operative time 200 minutes and mean blood loss 550 mL. Final histopathology showed organ-confined (pT2) disease in all patients; two (16.7%) had positive surgical margins, and four (33.3%) had nodal involvement. Continence was achieved in 10 patients (83%) at 1 year, while potency was regained in all 10 who underwent nerve-sparing surgery within 12 months. No patient developed biochemical recurrence at a mean follow-up of 25 months. Ten patients (83%) reported complete satisfaction with the procedure. Conclusions: Cytoreductive radical prostatectomy appears to be a safe and feasible component of multimodal therapy for carefully selected patients with oligometastatic prostate cancer. In this limited series, acceptable perioperative morbidity, encouraging early oncological outcomes and good functional recovery were observed, supporting its potential role in comprehensive disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.